Contrast Sensitivity and Color Vision as Biomarkers of the Preclinical Stage of Neurodegeneration in Huntington’s Disease

The aim of the study was to investigate contrast sensitivity (CS) and color vision in Huntington’s disease (HD), their correlation with clinical and genetic data, and the possibility of using the ophthalmological parameters as biomarkers of preclinical stage of neurodegeneration.

Materials and Methods. Participants in the study were divided into two groups, which included 44 HD subjects (main group) and 31 apparently healthy volunteers (control). In the main group, 21 subjects had pre-manifest and 23 manifest HD stage. The groups were age-, sex-, intraocular pressure-, and mean refractive error-matched. CAG (cytosine-adenine-guanine) repeat expansion size in the huntingtin gene, disease duration, and a motor function score according to the UHDRS were evaluated in HD patients. All patients underwent a thorough neurological and ophthalmic examination including CS evaluation using Freiburg Vision Test (FrACT), color vision assessment using Rabkin plates, and computer-assisted campimetry based on ApWay.ru Web platform.

Results. The range of the CAG repeat expansion size in the main group was 37–56 repeats (44.3±3.8), the UHDRS motor score 36.3±29.7, disease duration 13.7±7.2 years. CS in HD was reduced, there was a significant difference between the pre-manifest and manifest patients. The CS log inversely correlated with CAG repeat expansion size (r=–0.627; p=0.001). When reading Rabkin plates, HD patients made significantly more nonspecific mistakes than controls. Color differentiation thresholds in the HD group were higher than in the control group in red, green and blue colors. During computer-assisted campimetry, the manifest HD patients made significantly more mistakes in the stimulus shape differentiation giving oral answers than choosing on the screen. Color differentiation thresholds in green (r=0.489; p=0.003) and blue (r=0.416; p=0.014) correlated with the UHDRS score. When plotting ROC curves, the differentiation threshold for blue color had been established to have the best diagnostic value for distinguishing between the control and pre-manifest HD patients.

Conclusion. The study results indicate visual sensory deprivation in HD. Color vision disturbances develop early at the pre-manifest HD stage, ahead of the CS decrease signifying early damage to the parvocellular vision pathway. Amnestic aphasia in the manifest HD patients makes it difficult to obtain correct oral answers during visual function evaluation. Color differentiation thresholds proved to be a promising biomarker for early diagnosis of neurodegenerative processes.

1. McColgan P., Tabrizi S. Huntington’s disease: a clinical review. Eur J Neurol 2018; 25(1): 24–34, https://doi.org/10.1111/ene.13413.
2. Seliverstov Y., Dranitsyna M., Ivashynka A., Kravchenko M., Klyushnikov S., Illarioshkin S. Huntington disease in Russia: an epidemiological challenge? Neurology 2017; 88(Suppl 16): P4.323–P4.323.
3. Fisher E., Hayden M. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov Disord 2013; 29(1): 105–114, https://doi.org/10.1002/mds.25717.
4. Morrison P.J., Harding-Lester S., Bradley A. Uptake of Huntington disease predictive testing in a complete population. Clin Genet 2010; 80(3): 281–286, https://doi.org/10.1111/j.1399-0004.2010.01538.x.
5. Evans S., Douglas I., Rawlins M., Wexler N., Tabrizi S., Smeeth L. Prevalence of adult Huntington’s disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry 2013; 84(10): 1156–1160, https://doi.org/10.1136/jnnp-2012-304636.
6. Ivanova-Smolenskaia I.A., Ovchinnikov I.V., Illarioshkin S.N., Markova E.D., Kliushnikov S.A., Nikol’skaia N.N., Miklina N.I. Molecular-genetic testing in diagnosis of sporadic cases of Huntington’s disease. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova 1998; 98(3): 19–22.
7. Reilmann R., Leavitt B., Ross C. Diagnostic criteria for Huntington’s disease based on natural history. Mov Disord 2014; 29(11): 1335–1341, https://doi.org/10.1002/mds.26011.
8. Bates G., Dorsey R., Gusella J., Hayden M., Kay C., Leavitt B., Nance M., Ross C.A., Scahill R.I., Wetzel R., Wild E.J., Tabrizi S.J. Huntington disease. Nat Rev Dis Primers 2015; 1: 15005, https://doi.org/10.1038/nrdp.2015.5.
9. Ross C., Aylward E., Wild E., Langbehn D., Long J., Warner J., Scahill R.I., Leavitt B.R., Stout J.C., Paulsen J.S., Reilmann R., Unschuld P.G., Wexler A., Margolis R.L., Tabrizi S.J. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014; 10(4): 204–216, https://doi.org/10.1038/nrneurol.2014.24.
10. Ghosh R., Tabrizi S.J. Clinical features of Huntington’s disease. Adv Exp Med Biol 2018; 1049: 1–28, https://doi.org/10.1007/978-3-319-71779-1_1.
11. van Wijngaarden P., Hadoux X., Alwan M., Keel S., Dirani M. Emerging ocular biomarkers of Alzheimer disease. Clin Experiment Ophthalmol 2016; 45(1): 54–61, https://doi.org/10.1111/ceo.12872.
12. Kersten H., Roxburgh R., Danesh-Meyer H. Ophthalmic manifestations of inherited neurodegenerative disorders. Nat Rev Neurol 2014; 10(6): 349–362, https://doi.org/10.1038/nrneurol.2014.79.
13. Heidary G. Neuro-ophthalmic manifestations of pediatric neurodegenerative disease. J Neuroophthalmol 2017; 37: S4–S13, https://doi.org/10.1097/wno.0000000000000549.
14. Svetozarskiy S.N., Kopishinskaya S.V., Gustov A.V., Radyuk M.A., Antonova V.A., Smetankin I.G. Ophthalmic manifestations of Huntington’s disease. Vestnik oftal’mologii 2015; 131(5): 82–86, https://doi.org/10.17116/oftalma2015131582-86.
15. Kersten H., Danesh-Meyer H., Kilfoyle D., Roxburgh R. Optical coherence tomography findings in Huntington’s disease: a potential biomarker of disease progression. J Neurol 2015; 262(11): 2457–2465, https://doi.org/10.1007/s00415-015-7869-2.
16. Andrade C., Beato J., Monteiro A., Costa A., Penas S., Guimarães J., Reis F., Garrett C. Spectral-domain optical coherence tomography as a potential biomarker in Huntington’s disease. Mov Disord 2016; 31(3): 377–383, https://doi.org/10.1002/mds.26486.
17. Svetozarskiy S.N., Kopishinskaya S.V. Retinal optical coherence tomography in neurodegenerative diseases (review). Sovremennye tehnologii v medicine 2015; 7(1): 116–123, https://doi.org/10.17691/stm2015.7.1.14.
18. Batcha A.H., Greferath U., Jobling A.I., Vessey K.A., Ward M.M., Nithianantharajah J., Hannan A.J., Kalloniatis M., Fletcher E.L. Retinal dysfunction, photoreceptor protein dysregulation and neuronal remodelling in the R6/1 mouse model of Huntington’s disease. Neurobiol Dis 2012; 45(3): 887–896, https://doi.org/10.1016/j.nbd.2011.12.004.
19. O’Donnell B., Wilt M., Hake A., Stout J., Kirkwood S., Foroud T. Visual function in Huntington’s disease patients and presymptomatic gene carriers. Mov Disord 2003; 18(9): 1027–1034, https://doi.org/10.1002/mds.10491.
20. O’Donnell B.F., Blekher T.M., Weaver M., White K.M., Marshall J., Beristain X., Stout J.C., Gray J., Wojcieszek J.M., Foroud T.M. Visual perception in prediagnostic and early stage Huntington’s disease. J Int Neuropsychol Soc 2008; 14(03): 446–453, https://doi.org/10.1017/s1355617708080405.
21. Polevaya S.A., Parin S.B., Stromkova E.G. Psikhofizicheskoe kartirovanie funktsional’nykh sostoyaniy cheloveka. V kn.: Eksperimental’naya psikhologiya v Rossii: traditsii i perspektivy [Psychophysical mapping of human functional states. In: Experimental psychology in Russia: traditions and perspectives]. Pod red. Barabanshchikova V.A. [Barabanshchikov V.A. (editor)]. Moscow: Izd-vo “Institut psikhologii RAN”; 2010; p. 534–538.
22. Polevaya S., Parin S., Eremin E., Bulanov N., Chernova M., Parina I., Chikov M., Chernigovskaya T. Event-related telemetry (ERT) technology for study of cognitive functions. Int J Psychophysiol 2016; 108; 87–88, https://doi.org/10.1016/j.ijpsycho.2016.07.274.
23. Polevaya S.A., Parin S.B., Eremin E.V., Bulanov N.A., Chernova M.A. Razrabotka tekhnologii sobytiyno-svyazannoy telemetrii dlya issledovaniya kognitivnykh funktsiy. V kn.: XVIII Mezhdunarodnaya nauchno-tekhnicheskaya konferentsiya “Neyroinformatika–2016”. Chast’ 1 [Development of technology of event-related telemetry for the study of cognitive functions. In: XVIII International scientific and technical conference “Neuroinformatics–2016”]. Moscow: NIYaU MIFI; 2016; p. 34–44.
24. Parin S.B., Vetyugov V.V., Bakhchina А.V., Polevaya S.А. The role of the endogenous opioid system in the control of heart rate variability under cognitive loads of various levels. Sovremennye tehnologii v medicine 2014; 6(4): 116–126.
25. Ramamurthy M., Lakshminarayanan V. Human vision and perception. In: Handbook of advanced lighting technology. Springer International Publishing; 2015; p. 1–23, https://doi.org/10.1007/978-3-319-00295-8_46-1.
26. Bach M. The Freiburg Visual Acuity Test-variability unchanged by post-hoc re-analysis. Graefes Arch Clin Exp Ophthalmol 2007; 245(7): 965–971, https://doi.org/10.1007/s00417-006-0474-4.
27. Neargarder S., Stone E., Cronin-Golomb A., Oross S. the impact of acuity on performance of four clinical measures of contrast sensitivity in Alzheimer’s disease. The J Gerontol B Psychol Sci Soc Sci 2003; 58(1): P54–P62, https://doi.org/10.1093/geronb/58.1.p54.
28. Pentland A. Maximum likelihood estimation: the best PEST. Percept Psychophys 1980; 28(4): 377–379, https://doi.org/10.3758/bf03204398.
29. Takeda S., Tajime K., Taniguchi T. The Takeda Three Colors Combination Test: a screening test for detection of very mild Alzheimer’s disease. The Scientific World Journal 2014; 2014: 907316, https://doi.org/10.1155/2014/907316.
30. Bohnen N.I., Haugen J., Ridder A., Kotagal V., Albin R.L., Frey K.A., Müller M.L.T.M. Color discrimination errors associate with axial motor impairments in Parkinson’s disease. Mov Disord Clin Pract 2017; 4(6): 864–869, https://doi.org/10.1002/mdc3.12527.
31. Pelak V.S., Hills W. Vision in Alzheimer’s disease: a focus on the anterior afferent pathway. Neurodegener Dis Manag 2018; 8(1): 49–67, https://doi.org/10.2217/nmt-2017-0030.
32. Risacher S.L., WuDunn D., Pepin S.M., MaGee T.R., McDonald B.C., Flashman L.A., Wishart H.A., Pixley H.S., Rabin L.A., Paré N., Englert J.J., Schwartz E., Curtain J.R., West J.D., O’Neill D.P., Santulli R.B., Newman R.W., Saykin A.J. Visual contrast sensitivity in Alzheimer’s disease, mild cognitive impairment, and older adults with cognitive complaints. Neurobiol Aging 2013; 34(4): 1133–1144, https://doi.org/10.1016/j.neurobiolaging.2012.08.007.
33. Polo V., Rodrigo M.J., Garcia-Martin E., Otin S., Larrosa J.M., Fuertes M.I., Bambo M.P., Pablo L.E., Satue M. Visual dysfunction and its correlation with retinal changes in patients with Alzheimer’s disease. Eye 2017; 31(7): 1034–1041, https://doi.org/10.1038/eye.2017.23.
34. Nolan J.M., Loskutova E., Howard A.N., Moran R., Mulcahy R., Stack J., Bolger M., Dennison J., Akuffo K.O., Owens N., Thurnham D.I., Beatty S. Macular pigment, visual function, and macular disease among subjects with Alzheimer’s disease: an exploratory study. J Alzheimers Dis 2014; 42(4): 1191–1202, https://doi.org/10.3233/jad-140507.
35. Ridder A., Müller M., Kotagal V., Frey K., Albin R., Bohnen N. Impaired contrast sensitivity is associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord 2017; 34: 15–19, https://doi.org/10.1016/j.parkreldis.2016.10.006.
36. Ming W., Palidis D.J., Spering M., McKeown M.J. Visual contrast sensitivity in early-stage Parkinson’s disease. Invest Ophthalmol Vis Sci 2016; 57(13): 5696–5704, https://doi.org/10.1167/iovs.16-20025.
37. Artal P., Navarro R. Monochromatic modulation transfer function of the human eye for different pupil diameters: an analytical expression. J Opt Soc Am A Opt Image Sci Vis 1994; 11(1): 246, https://doi.org/10.1364/josaa.11.000246.
38. Clifford C.W.G. Visual perception: knowing what to expect. Curr Biol 2012; 22(7): R223–R225, https://doi.org/10.1016/j.cub.2012.02.019.
39. Massey T.H., Jones L. The central role of DNA damage and repair in CAG repeat diseases. Dis Model Mech 2018; 11(1): dmm031930, https://doi.org/10.1242/dmm.031930.
40. Копишинская С.В., Антонова В.А., Густов А.В. Бо­лезнь Гентингтона. Журнал неврологии и психиатрии им. C.C. Корсакова 2014; 114(1): 74–79. Kopshynskaya S.V., Antonova V.A., Gustov A.V. Huntington’s disease. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova 2014; 114(1): 74–79.
41. La Morgia C., Di Vito L., Carelli V., Carbonelli M. Patterns of retinal ganglion cell damage in neurodegenerative disorders: parvocellular vs magnocellular degeneration in optical coherence tomography studies. Front Neurol 2017; 8: 710, https://doi.org/10.3389/fneur.2017.00710.
42. Baake V., Reijntjes R., Dumas E., Thompson J., Roos R. Cognitive decline in Huntington’s disease expansion gene carriers. Cortex 2017; 95: 51–62, https://doi.org/10.1016/j.cortex.2017.07.017.
43. Fedotchev А.I., Parin S.B., Polevaya S.A., Velikova S.D. Brain-computer interface and neurofeedback technologies: current state, problems and clinical prospects (review). Sovremennye tehnologii v medicine 2017; 9(1): 175–184, https://doi.org/10.17691/stm2017.9.1.22.
44. Petukhov A., Polevaya S. Modeling of communicative individual interactions through the theory of information images. Current Psychology 2016; 36(3): 428–433, https://doi.org/10.1007/s12144-016-9431-5.

Svetozarskiy S.N. Contrast Sensitivity and Color Vision as Biomarkers of the Preclinical Stage of Neurodegeneration in Huntington’s Disease. Sovremennye tehnologii v medicine 2019; 11(2): 77, https://doi.org/10.17691/stm2019.11.2.11